Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. (2nd January 2021)

• Record Type: Journal Article
• Authors: Pollack, Megan; Keating, Karen; Wissinger, Erika; Jackson, Louis; Sarnes, Evelyn; Cuffel, Brian
• Is Part Of: Current medical research and opinion. Volume 37:Number 1(2021)
• Page Start: 59
• Page End: 70
• Publication Date: 2021-01-02
• Subjects: Solid tumor -- pan tumor -- neurotrophic receptor tyrosine kinase (NTRK) -- larotrectinib; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2020.1847057
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: The results from basket trials utilized to gain regulatory approval of tumor-agnostic therapies can be difficult to interpret without the context of a comparator arm. We describe the role and efficacy of histology-based treatments to provide a historical comparison with larotrectinib. Methods: A systematic literature review (SLR) was conducted on the clinical outcomes of current histology-based standard of care treatments used in non-small cell lung cancer, colorectal cancer, thyroid cancer, gliomas, soft tissue sarcoma, salivary gland cancer, and infantile fibrosarcoma (7 of the 21 tumor histologies in the larotrectinib trials). The review focused on advanced stage/metastatic disease to make a historical comparison with larotrectinib. Results: Larotrectinib provides positive outcomes in both adult and pediatric patients with advanced or metastatic solid tumors known to harbor NTRK gene fusions across a wide range of tumor types. Although the numbers of patients per tumor type are limited, the results of this historical comparison demonstrated that larotrectinib is an efficacious treatment option when naïvely indirectly compared with historical treatments across all 7 reviewed tumor types, especially in comparison to later lines of therapy. Conclusions: Utilizing larotrectinib as a case example across these types of historical comparisons shows that larotrectinib provides positive efficacy outcomes in TRK fusion cancer across tumor histologies known to harbor NTRK gene fusions that may be preferable to historical treatments.